Tue, Nov 25, 2014, 9:01 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Nektar Therapeutics (NKTR) Message Board

  • typecheck typecheck Nov 15, 2012 9:28 PM Flag

    What do you think of the CV risk cited by the FDA?

    FDA seems stubborn -- "drawn a hard line on the sand" about insisting on a very large, long term CV outcome trial for Relistor. They say it is a class affect on all mu opioid antagonist. Now how is that going to affect Naloxone? All the discussion seems to center on efficacy, which I don't doubt.

15.93+0.95(+6.34%)Nov 25 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.